文献速递消化道肿瘤放疗姑息放疗与转移瘤放疗物理与技术

剂量递增SBRT治疗交界可切除和局部晚期胰腺癌:多中心研究的可行性、安全性和初步临床结果

Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-02-23

这项前瞻性多中心研究在西班牙拉斯帕尔马斯省四所大学医院纳入BRPC/LAPC患者,采用标准直线加速器平台联合先进定位与肿瘤运动控制技术,实施45 Gy、50 Gy、55 Gy分5次连续每日照射的同步整合推量剂量递增方案。作者认为这些有希望的结果需更大样本量和更长随访的进一步研究确认。

要点

  • 45/50/55 Gy分5次SBRT剂量递增方案在BRPC/LAPC中可行,全部患者完成治疗。
  • 未观察到≥3级急性或晚期胃肠道毒性。

核心结论

  • 作者认为这些有希望的结果需更大样本量和更长随访期的进一步研究确认。

研究设计与样本

  • 前瞻性研究,纳入西班牙拉斯帕尔马斯省四所大学医院诊断为BRPC/LAPC、适合新辅助化疗和SBRT的患者。
  • 放疗使用标准直线加速器平台,采用先进定位(Lipiodol®和金属支架作为基准标记)和肿瘤运动控制(4D、DBH、Calypso®)。
  • 计划3个剂量递增SIB组:45 Gy/5次(9例)、50 Gy/5次(9+9例)、55 Gy/5次(9例)。
  • 主要终点为安全性和可行性,次要终点包括SBRT后影像学肿瘤反应、局部控制和生存。

主要发现

  • 2017年6月至2022年12月,四所参与中心共62例患者初始评估合格,49例适合化疗,41例化疗后转诊放疗,33例最终接受递增剂量SIB治疗:45 Gy组9例、50 Gy组16例、55 Gy组8例。
  • 全部患者完成计划治疗,未观察到≥3级急性或晚期胃肠道毒性。

局限性

  • 作者指出这些有希望的结果需更大样本量和更长随访期的进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pancreatic Stereotactic Body Radiotherapy (SBRT) allows for the administration of a higher biologically effective doses (BED), that would be essential to achieve durable tumor control. Escalating treatment doses need a very accurate tumor positioning and motion control during radiotherapy.The aim of this study to assess the feasibility and safety of a Simultaneous Integrated Boost (SIB) dose-escalated protocol at 45 Gy, 50 Gy and 55 Gy in 5 consecutive daily fractions, in Border Line Resectable Pancreatic Cancer (BRCP) /Locally Advanced Pancreatic Cancer (LAPC) by means of a standard LINAC platform. METHODS: Patients diagnosed of BRPC/LAPC, candidates for neoadjuvant chemotherapy and SBRT, in four university hospitals of the province of Las Palmas (Canary Islands, Spain) were included in this prospective study. Radiotherapy was administered using standard technology (LINACS) with advanced positioning (Lipiodol® and metallic stent used as fiducial markers) and tumor motion control (4D, DBH, Calypso®). There were 3 planned dose-escalated SIB groups, 45 Gy/5f (9 patients) 50 Gy/5f (9 + 9 patients) and 55 Gy/5f (9 patients). The defined primary end points of the study were the safety and feasibility of the proposed treatment protocol. Secondary endpoints included radiological tumor response after SBRT, local control and survival. RESULTS: From June 2017 to December 2022, sixty-two patients were initially assessed for eligibility in the study in the four participating centers, and 49 were candidates for chemotherapy (CHT). Forty-one were referred to radiotherapy after CHT and 33 finally were treated by escalated-dose SIB, 45 Gy (9 patients) 50 Gy (16 patients), 55 Gy(8 patients). All patients completed the scheduled treatment and no acute or late severe (≥grade3) gastrointestinal toxicity was observed.Local response was analyzed by CT/MRI two months after the end of SBRT. Ten patients (31,25 %) achieved objective response (2/9:45 Gy, 5/15:50 Gy, 3/8:55 Gy). Follow-up was closed as July 2023. Freedom from local progression at 1-2y were 89,3% (95 %CI:83,4-95,2%) and 66 % (95 %CI:54,6-77,4%) respectively. The 1-2y survival rates were 95,7% (95 %CI:91,4-100 % and 48,6% (95 %CI:37,7-59,5%) respectively. CONCLUSION: These promising results should be confirmed by further studies with larger sample size and extended follow-up period.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Salas B, Ferrera-Alayón L, Espinosa-López A, et al. Dose-escalated SBRT for borderline and locally advanced pancreatic cancer. Feasibility, safety and preliminary clinical results of a multicenter study. Clin Transl Radiat Oncol. 2024. PMID: 38433951. doi:10.1016/j.ctro.2024.100753

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。